KET-RO Plus RO DBT for Treatment Resistant Depression (KET-RO)

Pilot, non-randomised, single-group study combining IV ketamine (0.5 mg/kg over 40 minutes, four weekly infusions) with Radically Open DBT delivered over four months in adults with treatment-resistant depression (n=16).

Primary aims are safety and feasibility; assessments include adverse events, vitals (blood pressure), depressive symptom change and feasibility metrics for precision-medicine approaches.